Marijuana in the management of amyotrophic lateral sclerosis

American Journal of Hospice and Palliative Medicine

Volumn 18, Issue 4, 2001, Pages 264-270

  Carter, Gregory T ^a   Rosen, Bill S ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b St Vincent Health Care   (United States)

Author keywords

ALS; cannabidiol; cannabinoids; cannabinol; marijuana; symptom management

Indexed keywords

CANNABIS;

AMYOTROPHIC LATERAL SCLEROSIS; DRUG CONTROL; EVIDENCE BASED MEDICINE; HUMAN; LEGAL ASPECT; PATHOPHYSIOLOGY; PATIENT SELECTION; PHYTOTHERAPY; PSYCHOLOGICAL ASPECT; REVIEW; TREATMENT OUTCOME;

AMYOTROPHIC LATERAL SCLEROSIS; CANNABIS; DRUG AND NARCOTIC CONTROL; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT SELECTION; PHYTOTHERAPY; TREATMENT OUTCOME;

EID: 0035404366     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/104990910101800411     Document Type: Article

References (75)

1. Grinspoon L, Bakalar JB: Marihuana, the Forbidden Medicine. New Haven: Yale University Press, 1993.
2. Hollister LE: Interactions of cannabis with other drugs in man. In Braude MC, Ginzburg HM (eds.): Strategies for Research on the Interactions of Drugs of Abuse. National Institute on Drug Abuse Research Monograph 68. DHHS Pub. No. (ADM)86-1453. Washington, DC: Government Printing Office, 1986: 110-116.
3. Institute of Medicine: Division of Health Sciences Policy. Marijuana and Health: Report of a Study by a Committee of the Institute of Medicine, Division of Health Sciences Policy. Washington, DC: National Academy Press, 1982.
4. Public Health Service, Food and Drug Administration: FDA Guideline for the Clinical Evaluation of Analgesic Drugs. DHHS Pub. No. 93-3093. Rockville, MD: United States Department of Health and Human Services, 1992.
5. Beal JE, Olson DO, Laubenstein L, et al.: Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain & Symptom Management. 1995; 10: 89-97.
6. Foltin RW, Fischman MW, Byrne MF: Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite. 1988; 11: 1-14.
7. Greenberg I, Kuehnle J, Mendelson JH, Bernstein JG: Effects of marijuana use on body weight and caloric intake in humans. Psychopharmacology. 1976; 49: 79-84.
8. Nelson K, Walsh D, Deeter P, Sheehan F: A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliative Care. 1994; 10(1): 14-18.
9. Adams IB, Martin BR: Cannabis: Pharmacology and toxicology in animals and humans. Addiction. 1996; 91(11): 1585-1614.
10. Agurell S, Halldin M, Lindgren JE, et al.: Pharmacokinetics and metabolism of delta-1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev. 1986; 38(1): 21-43.
11. Johansson E, Halldin MM, Agurell S, et al.: Terminal elimination plasma half-life of delta-1-tetrahydrocannabinol (delta-1-THC) in heavy users of marijuana. Eur J Clin Pharmacol. 1989; 37(3): 273-277.
12. Thomas BF, Adams IB, Mascarella SW, et al.: Structure-activity analysis of anandamide analogs: Relationship to a cannabinoid pharmacophore. J Med Chem. 1996; 39(2): 471-497.
13. Mechoulam R, Devane WA, Breuer A, Zahalka J: A random walk through a cannabis field. Special Issue: Pharmacological, chemical, biochemical and behavioral research on cannabis and the cannabinoids. Pharmacol Biochem Behav. 1991; 40(3): 461-464.
14. Conrad C: Hemp for Health: The Medicinal and Nutritional Uses of Cannabis Sativa. Rochester, VT: Healing Arts Press, 1997.
15. Jones RT: Drug of abuse profile: Cannabis. Clin Chem. 1987; 33(Suppl 11): 72B-81B.
16. Jones RT, Benowitz NL, Herning RI: Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol. 1981; 21: 143S-152S.
17. Polen MR, Sidney S, Tekawa IS, et al.: Health care use by frequent marijuana smokers who do not smoke tobacco. West J Med. 1993; 158(6): 596-601.
18. Pope HG, Yurgelun-Todd D: The residual cognitive effects of heavy marijuana use in college students. JAMA. 1996; 275(7): 521-527.
19. Klein TW, Lane B, Newton CA, Friedman H: The cannabinoid system and cytokine network. Proc Soc Exp Biol Med. 2000; 225(1): 1-8.
20. Pertwee RG: Cannabinoid receptor ligands: Clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin Investig Drugs. 2000; 9(7): 1553-1571.
21. Akinshola BE, Chakrabarti A, Onaivi ES: In-vitro and in-vivo action of cannabinoids. Neurochem Res. 1999; 24(10): 1233-1240.
22. DiMarzo M, Bisogno T, DePetrocellis L: Endocannabinoids: New targets for drug development. Curr Pharm Des. 2000; 6(13): 1361-1380.
23. Carter GT: Rehabilitation management of neuromuscular disease. J Neuro Rehab. 1997; 11(2): 1-12.
24. Carter GT, Miller RG: Comprehensive management of amyotrophic lateral sclerosis. Physical Medicine & Rehabilitation Clinics of North America. Philadelphia: W.B. Saunders, 1998: 227-284.
25. Carter GT, Johnson ER, Bonekat HW, Lieberman JS: Laryngeal diversion in the treatment of intractable aspiration in motor neuron disease. Arch Phys Med Rehabil. 1992; 73(7): 680-682.
26. Carter GT: Neuromuscular disorders. In Dell Orto AE, Marinelli RP (eds.): Encyclopedia of Disability and Rehabilitation. New York: Macmillan, 1995: 509-515.
27. Miller RG, Rosenberg JA, Gelinas DF, et al.: Practice parameter: The care of patients with amyotrophic lateral sclerosis (an evidence-based review). Muscle Nerve. 1999; 22: 1104-1118.
28. Fowler WM, Carter GT, Kraft GH: Role of physiatry in the management of neuromuscular disease. Phys Med Rehabil Clin N Am 1998; 9(1): 1-8.
29. Klivenyi P, Ferrante RJ, et al.: Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Med. 1999; 5(3): 347-350.
30. Tarnopolsky M, Martin J: Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology. 1999; 52: 854-857.
31. Abresch RT, Seyden NK, Wineinger MA: Quality of life: Issues for persons with neuromuscular diseases. Physical Medicine & Rehabilitation Clinics of North America. Philadelphia: W.B. Saunders, 1998: 233-248.
32. Hillard CJ: Endocannabinoids and vascular function. J Pharmacol Exp Ther. 2000; 294(1): 27-32.
33. Meng ID, Manning BH, Martin WJ, Fields HL: An analgesia circuit activated by cannabinoids. Nature. 1998; 395(6700): 381-383.
34. Harvey DJ (ed.): Marihuana, “84: Satellite Symposium on Cannabis: Proceedings of the Oxford Symposium on Cannabis. Washington, DC: IRL Press, 1985: 45-54.
35. Rueda D, Galve-Roperh I, Haro A, Guzman M: The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol Pharmacol. 2000; 58(4): 814-820.
36. Noyes R, Brunk SF, Baram DA, Canter AC: Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol. 1975; 15(2-3): 139-143.
37. Zeltser R, Seltzer Z, Eisen A, et al.: Suppression of neuropathic pain behavior in rats by a non-psychotropic synthetic cannabinoid with NMDA receptor-blocking properties. Pain. 1991; 47(1): 95-103.
38. Noyes R, Brunk SF, Avery DAH, Canter AC: The analgesic properties of delta-9-tetrahydrocannabinol. Clin Pharmacol Ther. 1975; 18(1): 84-89.
39. Raft D, Gregg J, Ghia J, Harris L: Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Clin Pharmacol Ther. 1977; 21(1): 26-33.
40. Carter GT, Butler LM, Abresch RT, Ugalde VO: Expanding the role of hospice in the care of amyotrophic lateral sclerosis. American J Hospice & Palliative Care. 1999; 16(6): 707-710.
41. Mclaughlin PJ, Delevan CE, Carnicom S, et al.: Fine motor control in rats is disrupted by delta -9-tetrahydrocannabinol. Pharmacol Biochem Behav. 2000; 66(4): 803-809.
42. Herkenham M: Cannabinoid receptor localization in brain: Relationship to motor and reward systems. In Kalivas PW, Samson HH (eds.): The neurobiology of drug and alcohol addiction. Ann NY Acad Sci. 1992; 654: 19-32.
43. Richardson JD: Cannabinoids modulate pain by multiple mechanisms of action. J Pain. 2000; 1(1): 1-20.
44. Meinck HM, Schonle PW, Conrad B: Effects of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol. 1989; 263(2): 120-122.
45. Greenberg HS, Weiness AS, Pugh JE: Short term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther. 1994; 55: 324-328.
46. Hollister LE: Health aspects of cannabis. Pharmacol Rev. 1986; 38(1): 1-20.
47. Plasse TF, Gorter RW, Krasnow SH, et al.: Recent clinical experience with dronabinol. Pharmacol Biochem Behav. 1991; 40: 695-700.
48. Lichtman AH, Peart J, Poklis JL, et al.: Pharmacological evaluation of aerosolized cannabinoids in mice. Eur J Pharmacol. 2000; 399(2-3): 141-149.
49. Kelly P, Jones RT: Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol. 1992; 16: 228-235.
50. Jones RT: Cardiovascular effects of cannabinoids. In Harvey DJ (ed.): Marihuana, “84: Satellite Symposium on Cannabis: Proceedings of the Oxford Symposium on Cannabis. Oxford: IRL Press, 1985: 325-334.
51. Barnett G, Licko V, Thompson T: Behavioral pharmacokinetics of marijuana. Psychopharmacology. 1985; 85(1): 51-56.
52. Heishman SJ, Stitzer ML, Yingling JE: Effects of tetrahydrocannabinol content on marijuana smoking behavior, subjective reports, and performance. Pharmacol Biochem Behav. 1989; 34(1): 173-179.
53. Benowitz NL, Nguyen T, Jones RT, et al.: Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin Pharmacol Ther. 1980; 28: 115-120.
54. Herning RI, Hooker WD, Jones RT: Tetrahydrocannabinol content and differences in marijuana smoking behavior. Psychopharmacology. 1986; 90(2): 160-162.
55. Huestis MA, Henningfield JE, Cone EJ: Blood cannabinoids, Pt 1: Absorption of THC and formation of 11-OH-THC and THC COOH during and after smoking marijuana. J Anal Toxicol. 1992; 16(5): 276-282.
56. Huestis MA, Sampson AH, Holicky BJ, et al.: Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther. 1992; 52(1): 31-41.
57. Gruber AJ, Pope HG: Cannabis psychotic disorder: Does it exist? Am J Addict. 1994; 3(1): 72-83.
58. Benowitz NL, Jones RT: Effect of delta-9-tetrahydrocannabinol on drug distribution and metabolism: Antipyrine, pentobarbital and ethanol. Clin Pharmacol Ther. 1977; 22(3): 259-268.
59. Benowitz NL, Jones RT: Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. J Clin Pharmacol. 1981; 21: 214S-223S.
60. Hampson AJ, Grimaldi M, Axelrod J, Wink D: Cannabidiol and delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci. 1998; 95(14): 8268-8273.
61. Hampson AJ, Grimaldi M, Lolic M, et al.: Neuroprotective antioxidants from marijuana. Ann NY Acad Sci. 2000; 899: 274-282.
62. Nagayama T, Sinor AD, Simon RP, et al.: Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci. 1999; 19(8): 2987-2995.
63. Chen Y, Buck J: Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. J Pharmacol Exp Ther. 2000; 293(3): 807-812.
64. Eshhar N, Striem S, Biegon A: HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. Neuroreport. 1993; 5(3): 237-240.
65. Hollister LE: Marijuana and immunity. J Psychoactive Drugs. 1988; 20(1): 3-8.
66. Friedman H, Klein TW, Newton C, Daaka Y: Marijuana, receptors and immunomodulation. Adv Exp Med Biol. 1995; 373: 103-113.
67. Renn E, Mandel S, Mandel E: The medicinal uses of marijuana. Pharmacy & Therapeutics. 2000; 25(10): 536-544.
68. Gurley RJ, Aranow R, Katz M: Medicinal marijuana: a comprehensive review. J Psychoactive Drugs. 1998; 30(2): 137-147.
69. Voth EA, Schwartz RH: Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med. 1997; 126(10): 791-798.
70. Voelker R: Medical marijuana: A trial of science and politics. JAMA. 1994; 271(1): 1647-1648.
71. Voelker R: New marijuana laws in two states prompt caution. JAMA. 1996; 276(22): 1786-1788.
72. Landis NT: California, Arizona law permits medical use of marijuana: Police and health professionals wary about conflicts with federal law. Am J Health Syst Pharm. 1997; 54(2): 126-132.
73. Macready N: Two more US states approve cannabis. BMJ. 1996; 313(7067): 1224.
74. Hubbard JR, Franco SE, Onaivi ES: Marijuana: medical implications. Am Family Physician. 1999; 60(9): 2583-2588.
75. Robson P: Cannabis. Arch Dis Child. 1997; 77(2): 164-166.